A Plain Language Summary On the Effectiveness of Cladribine Tablets Compared With Other Oral Treatments for Multiple Sclerosis: Results From the Msbase Registry
Neurodegenerative Disease Management · 2023
DOI: 10.2217/nmt-2023-0005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurodegenerative Disease Management, 2023. Verfasst von Tim Spelman und 27 weiteren Autor:innen. Beteiligte Einrichtung: MSBase Foundation, Melbourne, Australia. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
WHAT IS THIS SUMMARY ABOUT?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments. WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS. WHAT DO THE RESULTS MEAN?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MSBase Foundation, Melbourne, Australia.
- Dokuz Eylul University, Izmir, Turkey.
- Amiri Hospital, Sharq, Kuwait.
- Department of Neurology 19 Mayis University, Samsun, Turkey.
- Liverpool Hospital, Sydney, Australia.
- University Hospital Ghent, Ghent, Belgium.
Zitieren
APA
Spelman, T., Ozakbas, S., Alroughani, R., Terzi, M., Hodgkinson, S., Laureys, G., Kalincik, T., Der Walt, A. V., Yamout, B., Lechner-Scott, J., Soysal, A., Kuhle, J., Sanchez-Menoyo, J. L., Morgado, Y. B., Spitaleri, D., Pesch, V. V., Horakova, D., Ampapa, R., Patti, F., …, & MSBase Study Group (2023). A Plain Language Summary On the Effectiveness of Cladribine Tablets Compared With Other Oral Treatments for Multiple Sclerosis: Results From the Msbase Registry. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2023-0005
Vancouver
Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, et al. A Plain Language Summary On the Effectiveness of Cladribine Tablets Compared With Other Oral Treatments for Multiple Sclerosis: Results From the Msbase Registry. Neurodegenerative Disease Management. 2023. doi:10.2217/nmt-2023-0005
BibTeX
@article{Spelman2023,
author = {Spelman, Tim and Ozakbas, Serkan and Alroughani, Raed and Terzi, Murat and Hodgkinson, Suzanne and Laureys, Guy and Kalincik, Tomas and Der Walt, Anneke Van and Yamout, Bassem and Lechner-Scott, Jeannette and Soysal, Aysun and Kuhle, Jens and Sanchez-Menoyo, Jose Luis and Morgado, Yolanda Blanco and Spitaleri, Daniele LA and Pesch, Vincent van and Horakova, Dana and Ampapa, Radek and Patti, Francesco and Macdonell, Richard and Al-Asmi, Abdullah and Gerlach, Oliver and Oh, Jiwon and Altintas, Ayse and Tundia, Namita and Wong, Schiffon L and Butzkueven, Helmut and MSBase Study Group, MSBase Study Group},
title = {A Plain Language Summary On the Effectiveness of Cladribine Tablets Compared With Other Oral Treatments for Multiple Sclerosis: Results From the Msbase Registry},
journal = {Neurodegenerative Disease Management},
year = {2023},
doi = {10.2217/nmt-2023-0005}
}
EUVIMED